Literature DB >> 25462230

In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors.

Leonardo Pisani1, Roberta Farina1, Orazio Nicolotti1, Domenico Gadaleta1, Ramon Soto-Otero2, Marco Catto1, Mario Di Braccio3, Estefania Mendez-Alvarez2, Angelo Carotti4.   

Abstract

Inhibition data on rat monoamine oxidase B isoform of a large number of 7-metahalobenzyloxy-2H-chromen-2-one derivatives (67 compounds) carrying at position 4 a variety of substituents differing in steric, electrostatic, lipophilic and H-bonding properties, were modeled by Gaussian field-based 3D-QSAR and docking simulations carried out on rat MAO-B homology model. The computational study combining two different approaches provided easily interpretable binding modes, highlighting the dominant role of the steric effects at position 4, and guided the design of new, potent and selective MAO-B inhibitors. The 4-hydroxyethyl-, 4-chloroethyl-, 4-carboxamidoethyl-coumarin derivatives 70, 71, and 76, respectively, were endowed with high MAO-B inhibitory potency (pIC50 = 8.13, 7.89 and 7.82, respectively) and good selectivity over MAO-A (pIC50 = 5.33, 3% inhibition at 10 μM, and pIC50 = 5.37, respectively). New compounds with moderate to low MAO-B inhibitory activity were also designed and prepared to challenge the predictive power of our docking-based 3D-QSAR model. The good match between predicted and experimental pIC50 values for all the newly designed compounds confirmed the robustness of our model (r(2) = 0.856, RMSE = 0.421) and its transparent rationale in unveiling the main molecular determinants for high potency towards MAO-B.
Copyright © 2014. Published by Elsevier Masson SAS.

Entities:  

Keywords:  3D-QSAR; 4-Substituted-7-(halo)benzyloxy-2H-chromene-2-ones; Molecular docking; Monoamine oxidase inhibitors; Parkinson's disease; Selective MAO-B inhibitors

Mesh:

Substances:

Year:  2014        PMID: 25462230     DOI: 10.1016/j.ejmech.2014.10.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors.

Authors:  Yeliz Demir; Feyzi Sinan Tokalı; Erbay Kalay; Cüneyt Türkeş; Pelin Tokalı; Osman Nuri Aslan; Kıvılcım Şendil; Şükrü Beydemir
Journal:  Mol Divers       Date:  2022-09-14       Impact factor: 3.364

Review 2.  Effects of Linkers and Substitutions on Multitarget Directed Ligands for Alzheimer's Diseases: Emerging Paradigms and Strategies.

Authors:  Narayanaperumal Pravin; Krzysztof Jozwiak
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

Review 3.  Computer-aided Drug Design Applied to Parkinson Targets.

Authors:  Hamilton M Ishiki; Jose Maria Barbosa Filho; Marcelo S da Silva; Marcus T Scotti; Luciana Scotti
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Novel C7-Substituted Coumarins as Selective Monoamine Oxidase Inhibitors: Discovery, Synthesis and Theoretical Simulation.

Authors:  Dong Wang; Ren-Yuan Hong; Mengyao Guo; Yi Liu; Nianhang Chen; Xun Li; De-Xin Kong
Journal:  Molecules       Date:  2019-11-05       Impact factor: 4.411

5.  Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent

Authors:  María Del Pilar Olaya; Nadezdha Esperanza Vergel; José Luis López; María Dolores Viña; Mario Francisco Guerrero
Journal:  Biomedica       Date:  2019-09-01       Impact factor: 0.935

6.  Chasing ChEs-MAO B Multi-Targeting 4-Aminomethyl-7-Benzyloxy-2H-Chromen-2-ones.

Authors:  Mariagrazia Rullo; Marco Catto; Antonio Carrieri; Modesto de Candia; Cosimo Damiano Altomare; Leonardo Pisani
Journal:  Molecules       Date:  2019-12-09       Impact factor: 4.411

7.  Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study.

Authors:  Tana Tandarić; Alja Prah; Jernej Stare; Janez Mavri; Robert Vianello
Journal:  Int J Mol Sci       Date:  2020-08-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.